Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
August 04, 2023 | 9:28 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has reiterated an Underweight rating on Genmab, maintaining a $33 price target. This could potentially impact the stock's performance.
The Underweight rating from Morgan Stanley suggests that they expect Genmab's stock to underperform compared to other stocks in the market. This could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100